Multiple Sclerosis Year In Review 2019

Pill bottles

Ofatumumab Bests Teriflunomide in Head-to-Head MS Trials

Findings from the phase 3 ASCLEPIOS I and II studies showed that treatment with ofatumumab (Novartis) resulted in a highly significant and clinically meaningful reduction in the number of confirmed relapses, compared with teriflunomide, a pyrimidine synthesis inhibitor, in patients with relapsing forms of multiple sclerosis.

AAN Issues Guideline Update for Immunization in Patients With MS

AAN has issued a practice guideline update for vaccine-preventable infections and immunizations for individuals with multiple sclerosis (MS). A subcommittee of the AAN — tasked with developing, disseminating and implementing these guidelines — found improvements and additions to the recommendations previously issued in 2002.
Next hm-section-front in Year in Review Multiple Sclerosis